U.S. overdose deaths dropped during 2018 for the first time in nearly two decades, the CDC said, in a sign that a nationwide epidemic of drug-related deaths is abating.
The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
A study commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that U.S. hospitals typically charge five times more for medications than their costs.
The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.
European Commission Approves Talzenna for Patients with Inherited BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.
A U.S. group that reviews the value of medicines issued a critical report on Novartis’ Mayzent, calling the new multiple sclerosis drug’s $88,561 list price “far out of line” compared with the product’s benefits for patients.
Merck & Co. Chief Executive Ken Frazier said a rule to base the price the U.S. government pays for some prescription drugs in Medicare on lower prices in other countries would face legal challenges if adopted.
Klick Health research found Google Assistant’s comprehension of the most commonly dispensed medication names in the U.S. was, on average, almost twice as accurate as Alexa and Siri’s.
Genentech announced positive topline results from the Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug MMF in patients with pemphigus vulgaris.
A Canadian advisory council studying prescription drug coverage said the federal government should create a universal, single-payer public pharmacare system, and warned that the current framework requires significant reforms.